Retrospective chart review of a referenced EEG database in assisting medication selection for treatment of depression in patients with eating disorders

Abstract Background: There is a noticeable lack of evidence regarding the impact of COVID-19 and the associated lockdown on young people with eating disorders. The goals of this study were 1) to examine characteristics of adolescents presenting for eating disorder (ED) assessment since the onset of the COVID-19 pandemic; 2) to compare adolescents presenting for ED assessment since the onset of the COVID-19 pandemic to those that presented for assessment one year previously; 3) to examine implications of the pandemic on the system of care. Methods: A retrospective chart review was completed on all patients assessed at a pediatric tertiary care ED program during the pandemic between April 1 and October 31, 2020, and on youth assessed during the same time frame one year previously. Data including body measurements and results of psychological measures was extracted from patients’ charts. Clinician reports were utilized for accounts of ED symptoms. Referrals to our program were also compared for the two time periods.Results: Of the 48 youth assessed between April and October 2020, average age was 14.6 years and average percentage of treatment goal weight was 77.7%. 40% cited the pandemic as a trigger for their ED; of these youth, 78.9% were medically unstable compared to 55.2% of those whose ED was not triggered by the pandemic. When comparing the 2020 cohort to those assessed in 2019, youth who presented for assessment during the pandemic trended towards having lower percentage of goal weights and higher rates of self-reported impairment, and were significantly more likely to be medically unstable and to require hospitalization. Higher rates of inpatient admissions, emergency room consultation requests and outpatient referrals deemed “urgent” were likewise associated with the pandemic period.

Download Full-text

Response to Dr. Tsai’s letter to the Editor – The use of referenced-EEG (rEEG) in assisting medication selection for the treatment of depression

Journal of Psychiatric Research ◽

10.1016/j.jpsychires.2010.09.011 ◽

2011 ◽

Vol 45 (1) ◽

pp. 134-135

Author(s):

Charles DeBattista ◽

Daniel A. Hoffman

Keyword(s):

Letter To The Editor ◽

Treatment Of Depression ◽

Medication Selection ◽

Selection For

Download Full-text

The use of referenced-EEG (rEEG) in assisting medication selection for the treatment of depression

Journal of Psychiatric Research ◽

10.1016/j.jpsychires.2010.05.009 ◽

2011 ◽

Vol 45 (1) ◽

pp. 64-75 ◽

Cited By ~ 26

Author(s):

Charles DeBattista ◽

Gustavo Kinrys ◽

Daniel Hoffman ◽

Corey Goldstein ◽

John Zajecka ◽

...

Keyword(s):

Treatment Of Depression ◽

Medication Selection ◽

Selection For

Download Full-text

The impact of COVID-19 on adolescents with eating disorders: a cohort study

Journal of Eating Disorders ◽

10.1186/s40337-021-00419-3 ◽

2021 ◽

Vol 9 (1) ◽

Author(s):

Wendy Spettigue ◽

Nicole Obeid ◽

Madison Erbach ◽

Stephen Feder ◽

Natalie Finner ◽

...

Keyword(s):

Eating Disorders ◽

Chart Review ◽

Clinical Course ◽

Tertiary Care ◽

Retrospective Chart Review ◽

Time Frame ◽

Lower Percentage ◽

Average Percentage ◽

Psychological Measures ◽

The Impact

Abstract Background There is a noticeable lack of evidence regarding the impact of COVID-19 and the associated lockdown on young people with eating disorders. The goals of this study were 1) to examine characteristics of adolescents presenting for eating disorder (ED) assessment since the onset of the COVID-19 pandemic; 2) to compare adolescents presenting for ED assessment since the onset of the COVID-19 pandemic to those that presented for assessment 1 year previously; 3) to examine implications of the pandemic on the system of care. Methods A retrospective chart review was completed on all patients assessed at a pediatric tertiary care ED program during the pandemic between April 1 and October 31, 2020, and on youth assessed during the same time frame 1 year previously. Data including body measurements and results of psychological measures was extracted from patients’ charts. Clinician reports were utilized for accounts of ED symptoms. Referrals to our program were also compared for the two time periods. Results Of the 48 youth assessed between April and October 2020, average age was 14.6 years and average percentage of treatment goal weight was 77.7%. 40% cited the pandemic as a trigger for their ED; of these youth, 78.9% were medically unstable compared to 55.2% of those whose ED was not triggered by the pandemic. When comparing the 2020 cohort to those assessed in 2019, youth who presented for assessment during the pandemic trended towards having lower percentage of goal weights and higher rates of self-reported impairment, and were significantly more likely to be medically unstable (p = 0.005) and to require hospitalization (p = 0.005). Higher rates of inpatient admissions, emergency room consultation requests and outpatient referrals deemed “urgent” were likewise associated with the pandemic period. Conclusions During the COVID-19 pandemic, youth assessed for an ED presented with high rates of medical instability and need for hospitalization. Caring for these youth may be more challenging during the pandemic, when access to services may be limited. Further research is required to better understand the impact of the pandemic on the clinical course and outcomes of EDs in adolescents.

Download Full-text

Psychotropic medication use at a private eating disorders treatment facility: A retrospective chart review and descriptive data analysis

Current Therapeutic Research ◽

10.1016/j.curtheres.2005.12.011 ◽

2005 ◽

Vol 66 (6) ◽

pp. 572-588 ◽

Cited By ~ 4

Author(s):

Kelly N. Gable ◽

Julie A. Dopheide

Keyword(s):

Eating Disorders ◽

Data Analysis ◽

Psychotropic Medication ◽

Chart Review ◽

Medication Use ◽

Retrospective Chart Review ◽

Treatment Facility ◽

Descriptive Data

Download Full-text

Selective Serotonin Reuptake Inhibitors for the Treatment of Depression in Adults with Down Syndrome: A Preliminary Retrospective Chart Review Study

Brain Sciences ◽

10.3390/brainsci11091216 ◽

2021 ◽

Vol 11 (9) ◽

pp. 1216

Author(s):

Robyn P. Thom ◽

Michelle L. Palumbo ◽

Claire Thompson ◽

Christopher J. McDougle ◽

Caitlin T. Ravichandran

Keyword(s):

Down Syndrome ◽

Adverse Effects ◽

Serotonin Reuptake ◽

Selective Serotonin Reuptake Inhibitors ◽

Chart Review ◽

Retrospective Chart Review ◽

Serotonin Reuptake Inhibitors ◽

Selective Serotonin ◽

Treatment Of Depression ◽

Review Study

Background: Depression is a common psychiatric comorbidity in individuals with Down syndrome (DS), particularly adults, with an estimated lifetime prevalence of at least 10%. The current literature on the treatment of depression in adults with DS is limited to case series published more than two decades ago, prior to the widespread use of modern antidepressant medications such as selective serotonin reuptake inhibitors (SSRIs). The purpose of this retrospective chart review study was to examine the effectiveness, tolerability, and safety of SSRIs for depression in adults with DS. Methods: Medical records of 11 adults with DS and depression were reviewed. Assignment of scores for severity (S) of symptoms of depression and improvement (I) of symptoms with treatment with an SSRI was made retrospectively using the Clinical Global Impression Scale (CGI). Demographic and clinical characteristics of the study population, SSRI name, dose, and duration of treatment; and adverse effects were also recorded. Results: All 11 patients (7 male, 4 female; mean age = 27.2 years, range 18–46 years) completed a 12-week treatment course with an SSRI. The median duration of time after initiation of the SSRI covered by record review was 2.1 years, with a range of 24 weeks to 6.7 years. Nine of the 11 patients (82%; 95% CI 52%, 95%) were judged responders to SSRIs based on a rating of “much improved” or “very much improved” on the CGI-I after 12 weeks of treatment (median time of follow-up was 14.4 weeks, with a range of 12.0–33.0 weeks). Adverse effects occurred in four patients (36%). The most common adverse effects were daytime sedation and anger. Conclusions: In this preliminary retrospective study, the majority of patients responded to a 12-week course of SSRI treatment and some tolerated long-term use. Controlled studies are needed to further assess the efficacy, tolerability, and safety of SSRIs for the treatment of depression in adults with DS.

Download Full-text